Private Asset Management Has Trimmed By $1.04 Million Its Bristol Myers Squibb (BMY) Holding; Tcw Strategic Income Fund (TSI) Shorts Lowered By 58.6%

June 18, 2018 - By Kurt Siggers

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Tcw Strategic Income Fund Inc (NYSE:TSI) had a decrease of 58.6% in short interest. TSI’s SI was 7,700 shares in June as released by FINRA. Its down 58.6% from 18,600 shares previously. With 62,500 avg volume, 0 days are for Tcw Strategic Income Fund Inc (NYSE:TSI)’s short sellers to cover TSI’s short positions. The stock increased 0.37% or $0.02 during the last trading session, reaching $5.47. About 38,015 shares traded. TCW Strategic Income Fund, Inc. (NYSE:TSI) has declined 0.71% since June 18, 2017 and is downtrending. It has underperformed by 13.28% the S&P500.

Private Asset Management Inc decreased Bristol Myers Squibb (BMY) stake by 9.83% reported in 2018Q1 SEC filing. Private Asset Management Inc sold 16,541 shares as Bristol Myers Squibb (BMY)’s stock declined 23.11%. The Private Asset Management Inc holds 151,740 shares with $9.60 million value, down from 168,281 last quarter. Bristol Myers Squibb now has $89.57 billion valuation. The stock increased 2.18% or $1.17 during the last trading session, reaching $54.8. About 14.50 million shares traded or 62.77% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 2.98% since June 18, 2017 and is downtrending. It has underperformed by 15.55% the S&P500. Some Historical BMY News: ; 09/04/2018 – #2 Merck racks up another win in wide-ranging PhIII Keytruda lung cancer study, this time as solo therapy $MRK $BMY; 23/04/2018 – Merck: EMA Validates Type II Variation for KEYTRUDA in Combination With Pemetrexed and Platinum Chemotherapy; 16/04/2018 – Merck & Co. Cements Lead in Lung Cancer as Bristol-Myers Fizzles; 23/04/2018 – DJ Bristol-Myers Squibb Company, Inst Holders, 1Q 2018 (BMY); 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 08/05/2018 – NEON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN CLINICAL TRIAL EVALUATING PERSONAL CANCER VACCINE NEO-PV-01 IN COMBINATION WITH KEYTRUDA┬« (PEMBROLIZUMAB) AND CHEMOTHERAPY; 26/04/2018 – BRISTOL-MYERS SQUIBB CO BMY.N SEES FY 2018 GAAP SHR $2.70 TO $2.80; 12/03/2018 – Rhode Island DoA: Bristol Fourth of July Committee Mon, 3/12/2018, 8:30 PM; 13/04/2018 – BMY: OPDIVO SHOWED STAT SIG BENEFIT VERSUS DOCETAXEL; 05/03/2018 – Rhode Island DoA: Bristol Warren Regional School District Mon, 3/5/2018, 6:00 PM

Investors sentiment decreased to 1 in Q1 2018. Its down 0.42, from 1.42 in 2017Q4. It worsened, as 4 investors sold TCW Strategic Income Fund, Inc. shares while 12 reduced holdings. 4 funds opened positions while 12 raised stakes. 8.46 million shares or 3.04% more from 8.21 million shares in 2017Q4 were reported. Ameriprise Inc invested in 0% or 102,193 shares. Aviance Capital Ltd Limited Liability Company accumulated 12,415 shares. Dorsey & Whitney Trust Co Limited holds 0.04% of its portfolio in TCW Strategic Income Fund, Inc. (NYSE:TSI) for 35,878 shares. Focused Wealth owns 10,551 shares. Monroe Commercial Bank & Mi reported 5,400 shares. Us National Bank & Trust De has invested 0% in TCW Strategic Income Fund, Inc. (NYSE:TSI). Guggenheim Ltd accumulated 71,055 shares. Citigroup holds 6,000 shares or 0% of its portfolio. Dixon Hubard Feinour Brown Va holds 185,600 shares or 0.29% of its portfolio. Northside Capital Mngmt Limited Liability Com holds 2.65% or 1.45 million shares in its portfolio. Fiduciary has 0.02% invested in TCW Strategic Income Fund, Inc. (NYSE:TSI) for 143,068 shares. Provise Ltd Com has invested 0.03% in TCW Strategic Income Fund, Inc. (NYSE:TSI). First Manhattan reported 136,073 shares stake. Benjamin F Edwards has invested 0.07% in TCW Strategic Income Fund, Inc. (NYSE:TSI). North Star Inv Mgmt accumulated 0.02% or 36,712 shares.

Since January 8, 2018, it had 6 insider buys, and 0 selling transactions for $993,471 activity. Landmann Laird had bought 10,536 shares worth $58,641 on Wednesday, March 21. Kane Steve had bought 10,718 shares worth $59,806. Shares for $54,670 were bought by MCMILLAN PETER on Wednesday, February 21.

Since April 30, 2018, it had 1 buy, and 0 insider sales for $249,948 activity. Another trade for 4,770 shares valued at $249,948 was made by Paliwal Dinesh C on Monday, April 30.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on July, 26. They expect $0.87 earnings per share, up 17.57% or $0.13 from last year’s $0.74 per share. BMY’s profit will be $1.42B for 15.75 P/E if the $0.87 EPS becomes a reality. After $0.94 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -7.45% negative EPS growth.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Hilliard Lyons on Tuesday, September 12. The rating was initiated by Atlantic Securities on Friday, December 18 with “Underweight”. BMO Capital Markets maintained the shares of BMY in report on Wednesday, August 16 with “Sell” rating. Cowen & Co maintained the stock with “Hold” rating in Monday, July 10 report. Credit Suisse maintained the stock with “Neutral” rating in Friday, October 27 report. On Monday, May 23 the stock rating was initiated by Hilliard Lyons with “Neutral”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Outperform” rating given on Monday, May 9 by Credit Suisse. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, April 5 report. The rating was maintained by Jefferies on Thursday, July 14 with “Hold”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Friday, September 22 by Piper Jaffray.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: which released: “Bristol-Myers Top NASH Contenders” on June 12, 2018, also with their article: “Merck up 2% premarket on positive Keytruda data; Bristol-Myers down 2%” published on June 04, 2018, published: “Bristol-Myers Squibb (BMY) Presents at UBS Global Healthcare Conference (Transcript)” on May 22, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: and their article: “Neon Therapeutics readies IPO” published on June 01, 2018 as well as‘s news article titled: “Bristol-Myers Squibb (BMY) Says China National Drug Administration Approved Country’s First Immuno-Oncology …” with publication date: June 15, 2018.

Investors sentiment decreased to 0.83 in 2018 Q1. Its down 0.11, from 0.94 in 2017Q4. It dived, as 64 investors sold BMY shares while 573 reduced holdings. 111 funds opened positions while 418 raised stakes. 1.12 billion shares or 1.08% more from 1.11 billion shares in 2017Q4 were reported. 1St Source Bancshares accumulated 71,353 shares. Oarsman has invested 0.11% in Bristol-Myers Squibb Company (NYSE:BMY). Teachers Retirement Of The State Of Kentucky, a Kentucky-based fund reported 291,984 shares. Illinois-based Balasa Dinverno Foltz Llc has invested 0.24% in Bristol-Myers Squibb Company (NYSE:BMY). Weatherly Asset Mgmt Lp, California-based fund reported 4,756 shares. Forbes J M And Communication Llp holds 0.2% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 13,533 shares. 800 are held by Alphamark Advisors Ltd Company. Godshalk Welsh Mgmt holds 3,950 shares. Axa, France-based fund reported 319,516 shares. Bremer Trust National Association has 10,650 shares. Goldman Sachs Grp Incorporated stated it has 0.23% in Bristol-Myers Squibb Company (NYSE:BMY). Fairpointe Cap Llc reported 0.01% stake. State Of Wisconsin Invest Board has invested 0.38% in Bristol-Myers Squibb Company (NYSE:BMY). Great Lakes Advsrs Limited Liability Company reported 162,242 shares or 0.24% of all its holdings. Cullinan Assocs reported 0.57% stake.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts